



# The Role of the Microbiome and Allergic Disease in Premature Infants

Kate Luskin, MD

Scripps Allergy-Immunology Fellow, PGY-6

# Outline

- Background on microbiome and the association with atopy
- Study design
- Preliminary findings
- Future directions

# Association Between Microbiome and Atopic Disease

- Asthma: most common chronic disease in pediatrics
  - Greater risk in pre-term
- Food allergy: early exposure recommended
  - Prevalence appears to be rising  $\sim 1.2\%$ /decade
- Microbiome:
  - Hygiene hypothesis - increased susceptibility to allergic disease with lack of early childhood exposure to infection, symbiotic micro-organisms and parasites
  - Lower rates of allergic disease:
    - Antibiotics
    - Exclusive breastfeeding for first 4 months
    - Vaginal delivery
    - Furry pets

# Microbiome Components

- Microbiome: sum of microbes, genomic elements and interactions in a given ecological niche
  - $10^6$  microbe genes vs 2300 human genes
- Definitions
  - Probiotic: live microbes
  - Prebiotic: non-digestible compounds (HMOs)
  - Synbiotic: pro- + prebiotic
- Symbiosis:
  - Modulate type II immunity
  - Intestinal barrier function
  - Mucosal immune system

# Dysbiosis – Affects on Food Allergy and Occurrence in Prematurity

- Microbiome alterations: antibiotics, diet, infections, bacterial exposure
- Dysbiosis
  - Change in food allergy outcomes
  - Timing – first 100 days of life <sup>1</sup>
- Prematurity:
  - Development in the hospital
  - Multiple insults
  - Microbiome ~ # NICU days <sup>2</sup>

1. Arrieta, M.C. (2015). Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med*, 7(307): 1-14

2. Neu, J. (2015). Preterm infant nutrition, gut bacteria and necrotizing enterocolitis. *Curr Opin Clin Nutr*, 18(3): 285-88.

# The Association Between Milk Feedings in the Preterm Population, the Microbiome and Risk of Atopic Disease

- Prospective cohort study
- Hypotheses:
  - Specific microbiome pattern will be affected by nutrition, antibiotics and acid suppressive meds
  - Microbiome patterns will be associated with the development of atopic disease
  - Correlate maternal diet with presence of breast milk peptides
- Inclusion:  $\leq 34$  WGA, BW  $\leq 2000$  g in NICU
- Exclusion: major congenital abnormalities on GI tract or precluding trial completion, HIE

Procedures	NICU	NICU Discharge	4 months	12 months	24 months	4-6 years
Consent	•					
Medical History	•	•	•	•	•	•
Gestational Age	•	•				
Adjusted Age	•	•	•	•	•	•
Growth Parameters	•	•	•	•	•	•
Demographics	•	•	•	•	•	•
Stool Sample	•	•	•	•	•	•
Milk Sample	•	•	•	•		
Oral Sample	•	•	•	•		
ISAAC Questionnaires			•	•	•	•
ImmunoCAP Multiple Allergen			•	•	•	
History and Allergy Questionnaire	•					
Visit Questionnaire			•	•	•	•

# Milk Analysis

- Mass Spectrometry
- University of Nebraska protein database

```
NP_000468.1      MKWVTFISLLFLFSSAYSRGVFRDDAHKSEVAHRFKDLGEEFKALVLI AFAQYLQQCPF
NP_051335.1      MKWVTFISLLLLLFFSSAYSRGVFRDDTHKSEIAHRFKDLGEEHFKGLVLI AFSQYLQQCPF
NP_001005208.1  MKWVTFISLLFLFSSAYSRGVFRDDTYKSEIAHRFKDLGEQYFKGLVLI AFSQHLQQCPY
*****:*****:***:*****: **.*****:*****:
NP_000468.1      EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAQKQP
NP_051335.1      DEHVKLVNELTEFAKTCVADESHAGCEKSLHTLFGDELCKVASLRETYGDMADCCCKQP
NP_001005208.1  EEHVKLVREVTEFAKTCVADESAENCDKSIHTLFGDKLCAIPSLREHYGDLADCCKEEP
:*****.*:***** .***:*****:*.*** **:*:***** **
NP_000468.1      ERNECFLQHKDDNPDLRPLRPEVDVMCTAFHDNEETFLKKYLYEIAARRHPYFYAPELLF
NP_051335.1      ERNECFLSHKDDSPDLPKL-KPDPNTLCDEFKADEKKFWGKYLEIARRHPYFYAPELLY
NP_001005208.1  ERNECFLQHKNDNPDIPLK-KPDPVALCADFQEDQKFWGKYLEIARRHPYFYAPELLY
*****.*:*.***:*.*** .*** .*** **:*:*****:*****:
```

Protein Group	Protein ID	Accession	-10lgP	Coverage (%)	Coverage (%) Sample 2	Area Sample 2	#Peptides	#Unique	#Spec Sample 2	PTM	Avg. Mass	Description
1	3	<a href="#">P02788 TRFL_HUMAN</a>	442.15	84	84	5.99E10	223	216	7478	Y	78182	Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6
9	7	<a href="#">P49327 FAS_HUMAN</a>	392.45	63	63	1.73E9	125	124	1023	Y	273424	Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3
5	4	<a href="#">P47989 XDH_HUMAN</a>	378.34	66	66	3.26E9	104	103	1251	Y	146424	Xanthine dehydrogenase/oxidase OS=Homo sapiens GN=XDH PE=1 SV=4
3	24	<a href="#">P05814 CASB_HUMAN</a>	364.22	88	88	7.79E10	199	199	2983	Y	25382	Beta-casein OS=Homo sapiens GN=CSN2 PE=1 SV=4
4	5	<a href="#">P01833 PIGR_HUMAN</a>	354.99	64	64	4.91E9	89	89	1280	Y	83284	Polymeric immunoglobulin receptor OS=Homo sapiens GN=PIGR PE=1 SV=4
16	6	<a href="#">P19835 CEL_HUMAN</a>	345.13	52	52	2.56E9	68	68	726	Y	79322	Bile salt-activated lipase OS=Homo sapiens GN=CEL PE=1 SV=3
20	22	<a href="#">P0C0L5 CO4B_HUMAN</a>	339.24	47	47	5.39E6	66	3	348	Y	192750	Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2
21	23	<a href="#">P0C0L4 CO4A_HUMAN</a>	337.17	47	47	3.8E6	66	3	345	Y	192784	Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2
7	10	<a href="#">P02768 ALBU_HUMAN</a>	334.76	78	78	3.51E9	82	59	1185	Y	69367	Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2
13	1	<a href="#">P13645 K1C10_HUMAN</a>	334.14	62	62	1.42E9	56	42	796	Y	58827	Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6
27	12	<a href="#">P01024 CO3_HUMAN</a>	332.73	47	47	1.52E8	62	61	205	Y	187147	Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2
12	11	<a href="#">P04264 K2C1_HUMAN</a>	330.94	67	67	1.31E9	62	52	773	Y	66039	Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6
22	13	<a href="#">P22897 MRC1_HUMAN</a>	327.94	47	47	3.45E8	61	61	349	Y	166011	Macrophage mannose receptor 1 OS=Homo sapiens GN=MRC1 PE=1 SV=1
11	8	<a href="#">Q08431 MFGM_HUMAN</a>	326.16	85	85	2.9E9	52	52	876	Y	43123	Lactadherin OS=Homo sapiens GN=MFG8 PE=1 SV=2
2	101	<a href="#">P00709 LALBA_HUMAN</a>	321.20	80	80	4.41E10	59	58	3251	Y	16225	Alpha-lactalbumin OS=Homo sapiens GN=LALBA PE=1 SV=1
19	9	<a href="#">P35908 K22E_HUMAN</a>	319.10	80	80	5.21E8	57	45	405	Y	65433	Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2
14	21	<a href="#">Q13410 BT1A1_HUMAN</a>	313.58	55	55	2.72E9	52	51	825	Y	58960	Butyrophilin subfamily 1 member A1 OS=Homo sapiens GN=BTN1A1 PE=1 SV=3
17	2	<a href="#">P35527 K1C9_HUMAN</a>	313.17	77	77	8.59E8	43	42	548	Y	62064	Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3
23	28	<a href="#">Q99541 PLIN2_HUMAN</a>	297.97	74	74	9.18E8	37	37	392	Y	48075	Perilipin-2 OS=Homo sapiens GN=PLIN2 PE=1 SV=2
15	33	<a href="#">P01876 IGHA1_HUMAN</a>	289.28	76	76	1.69E9	40	17	726	Y	37655	Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2
6	130	<a href="#">P61626 LYSC_HUMAN</a>	289.24	68	68	8.29E9	46	46	1265	Y	16537	Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1
8	68	<a href="#">P47710 CASA1_HUMAN</a>	285.46	65	65	7.34E9	47	47	1121	Y	21671	Alpha-S1-casein OS=Homo sapiens GN=CSN1S1 PE=1 SV=1
10	109	<a href="#">P07498 CASK_HUMAN</a>	283.51	62	62	1.03E10	50	50	905	Y	20305	Kappa-casein OS=Homo sapiens GN=CSN3 PE=1 SV=3
35	19	<a href="#">P02533 K1C14_HUMAN</a>	280.33	66	66	1.72E7	37	2	203	Y	51562	Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4
26	14	<a href="#">P48668 K2C6C_HUMAN</a>	280.18	53	53	1.49E6	34	1	192	Y	60025	Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 SV=3
30	16	<a href="#">P02538 K2C6A_HUMAN</a>	279.00	50	50	2.32E6	33	2	192	Y	60045	Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3
28	25	<a href="#">P13647 K2C5_HUMAN</a>	276.95	54	54	5.06E7	34	19	203	Y	62378	Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3
34	29	<a href="#">P02787 TRFE_HUMAN</a>	274.93	44	44	1.29E8	29	27	230	Y	77064	Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3

# Milk Protein Alignment

**AKH04310.1**

[Protein Coverage](#) | [Supporting Peptides](#) |

## Protein Coverage:

1 MKLFALLALVVLLAGVQSQKDPKLVPESTLLRLEWKFDDIADECERFLAPKGYAGVQVSPVHKNLLYTATAPGLWERY  
81 QPMSYKLVSRSGDETAFRDMVRRRCNAVGVRIYVDVVLNHMSGNWDNAVGTGGSTADTYNYSYPGVDPYDHSDFHPYCILND  
161 YQDPEIVRNCELVGLHDLQSQDYVREKLIDFLNHLVDAGVAGFRVDAAKHMWPADLEYIYGKVNRRNSDAGYCGDSSPS  
241 RYQEVIDLGGEA VSKFEYNGFGRVTEFKHSEQIGYAFRGNRLEWYTYKPNWGLLPSGD **ALVFVDNHDNQR**GGGNAILT  
321 YKTPKNYKMAIAFILAHYPYGYPRVMSSFDFAHDQGGPPQSDKNILSPSINADGTCGNGWVCEHRWRQHANMVGFRNAVR  
401 GTEITNWDNGNHQIGFCRGRGFVAFNVEDNDLKQTLQTCPLAGTYCDVISGSKNNRAHLGAELVVAPNGEAFSVRLIS  
481 DDDGVLAIHLEEKL

## Supporting Peptides:

Peptide	Uniq	-10lgP	Mass	Length	ppm	m/z	z	RT	Fraction	Scan	Source File	Area Sample 2	#Spec	#Spec Sample 2	Start	End	PTM
D.ALVFVDNHDNQR.G	N	57.31	1426.6953	12	5.7	714.3590	2	33.37	3	23088	Milk_1081.raw	2.26E6	3	3	301	312	
L.VFVDNHDNQR.G	N	39.93	1242.5741	10	6.1	622.2981	2	33.33	3	23048	Milk_1081.raw	9.88E4	1	1	303	312	

**total 2 peptides**

# Sample Analyses

- All 4 samples:
  - *Bos taurus* (cow), *Felis catus* (cat), *Canis lupus familiaris* (dog), *Salmo salar* (salmon), *Equus caballus* (horse), *Tyrophagus putrescentiae* (mold/cheese mite), *Aedes aegypti* (mosquito), *D farinae*, *D pteronyssinus*, *Hevea brasiliensis* (rubber), *Procambarus clarkia* (crayfish)
- 3/4 samples:
  - *Sus scrofa* (pig), *Cladosporium*, *Gallus gallus* (chicken), *Scylla paramamosain* (crab)
- 2/4 samples:
  - *Oreochromis mossambicus* (tilapia), *Prunus dulcis* (almond), *Crangon crangon* (shrimp), *Triticum aestivum*
- 1/4 samples:
  - *Thunia alba* (orchid), *Periplaneta americana* (cockroach), *Catharanthus roseus* (periwinkle), *Phleum pratense* (timothy grass), *Penicillium citrinum*, *Curvularia lunata* (mold), *Daucus carota* (wild carrot), *Oryza sativa* (rice), *Brassica rapa* (cabbage)

# Take-Away Points

- Changes in the microbiome have been associated with different outcomes in asthma, eczema and food allergy
- Premature infants are a special population who are at higher risk for asthma and microbial dysbiosis
- There is a lack of knowledge regarding the role of maternal breast milk in fostering a favorable microbiome profile and its role in allergic sensitization

# Future Plans

- Find sequences for all allergenic proteins
- Correlate maternal diet with results from breast milk samples
  - Serial runs on same donor
- Analyze NICU data
  
- Incorporate HMOs, post-translational modifications into analysis?

# Acknowledgements

- Dr. Sydney Leibel, UCSD
- Dr. Sandra Leibel, UCSD
- Dr. Bob Geng, UCSD
- Dr. Andrew White, Scripps

# References

- Arrieta, M.C., Stiemsma, L.T., Dimitriu, P.A. *et al.* (2015). Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med*, 7(307): 1-14.
- Been, J.V., Lugtenberg, M.J., Smets, E. *et al* (2014). Preterm birth and childhood wheezing disorders: A systematic review and meta-analysis. *PLoS Med*, 11(1): 1-18.
- Braman, S.S. (2006). The global burden of asthma. *Chest*, 130(1): 4S-12S.
- Carpenter, L., Beral, V., Ebi-Kryston, K.L *et al* (1989). Respiratory symptoms as predictors of 27 year mortality in a representative sample of British adults. *BMJ*, 299 (6695):357-361.
- Fujimura, K.E., Johnson, C., Ownby, D.R. *et al* (2011). Man's best friend? The effect of pet ownership on house dust microbial communities. *J Allergy Clin Immunol.*, 126(2) 410–412.
- Griffiths, R.L.M., El-Shanawany, T., Jolles, S.R.A. *et al* (2017). Comparison of the performance of skin prick, ImmunoCAP, and ISAC tests in the diagnosis of patients with allergy. *Int Arch Allergy Immunol*, 172(4): 215-223.
- Jeurink, P.V., van Esch, B.C., Rijiniere, A. *et al* (2013). Mechanisms underlying immune effects of dietary oligosaccharides. *Am J Clin Nutr.*, 98(2):572S-757S
- Lynch, S.V., Wood, R.A., Boushey, L.B. *et al* (2014). Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. *J Allergy Clin Immunol.*, 134(3): 593–601.
- Molloy, J., Allen, K., Collier, F. *et al* (2013). The potential link between gut microbiota and IgE-mediated food allergy in early life. *Int J Environ Res Public Health*, 10(12): 7235-7256.
- Moukarzel, S., Bode, L. (2017). Human milk oligosaccharides and the preterm infant: A journey in sickness and in health. *Clin Perinatol.*, 44(1):193-207.
- Neu, J. (2015). Preterm infant nutrition, gut bacteria, and necrotizing enterocolitis, *Curr Opin Clin Nutr Metab Care*, 18(3): 285–288
- Raciborski, F., Tomaszewska, A., Komorowski, J. (2012). The relationship between antibiotic therapy in early childhood and the symptoms of allergy in children aged 6-8 years: The questionnaire study results. *Int J Occup Med Environ Health*, 25(4): 470–480.
- Rivas, M.N., Burton, O.T., Wise, P. (2013). A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. *J Allergy Clin Immunol*, 131(1): 201-212.
- Roduit C., Scholtens, S., de Jongste, J.C. (2009). Asthma and 8 years of age in children born by caesarian section. *Thorax*, 64(2): 107–113.
- Savage, J., Johns, C.B. (2015). Food allergy: Epidemiology and natural history. *Immunol Allergy Clin North Am*, 35(1): 45-59.
- Silvers, K.M., Frampton, C.M., Wickens, K. *et al* (2012). Breastfeeding protects against current asthma up to 6 years of age. *J Pediatr.*, 160(6): 991–996.